Curator
@puzzle4sb9
Moderna's shares surged on Tuesday, surpassing their 50-day average for the first time since June. With news of the first U.S. death linked to bird flu, investors are optimistic about the potential sales boost from the company's H5N1 vaccine development.
0 reply
0 recast
0 reaction